Paradigm to present at NWR Healthcare Conference
Released
Released
Announcement PDF
ASX RELEASE
18th March 2025
Paradigm to present at NWR Virtual Healthcare
Conference
Paradigm Biopharmaceuticals Ltd (ASX: PAR) (“Paradigm” or “the Company”), a
late-stage drug development company focused on delivering new therapies to address
unmet medical needs, is pleased to announce that it will present at the NWR Virtual
Healthcare Conference.
Chief Medical Officer Dr Donna Skerrett will present to the conference at 11:40am AEDT
on Wednesday 19 March 2025.
Shareholders, investors and interested parties are encouraged to register to attend the
presentation at the following link:
https://us02web.zoom.us/webinar/register/WN_fdxVjCljRP2_QKbwe04WuQ
A recording will be available at the above link shortly after the conclusion of the live
session, and the replay will also be available via the Company’s website and social media
channels.
Questions can be submitted on the day or sent in advance to:
matt@nwrcommunications.com.au
For more information please visit: https://nwrcommunications.com/healthconf
A copy of the presentation for the webinar is attached to this announcement or available
via the paradigm website:
https://paradigmbiopharma.com/performance-progress/#announcements.
About Paradigm Biopharmaceuticals
Paradigm Biopharmaceuticals Ltd. (ASX: PAR) is a late-stage drug development
company driven by a purpose to improve patients’ health and quality of life by
discovering, developing, and delivering pharmaceutical therapies. Paradigm’s focus is
developing injectable (subcutaneous) pentosan polysulfate sodium (iPPS) for the
treatment of diseases with inflammatory pathogenesis, where the anti-inflammatory and
chondroprotective properties of iPPS may be transformative to current care.
Authorised for release by the Paul Rennie, Paradigm Chair and Managing Director Paradigm
To learn more please visit: www.paradigmbiopharma.com
FOR FURTHER INFORMATION PLEASE CONTACT:
Simon White
Director of Investor Relations
Tel: +61 404 216 467
Paradigm Biopharmaceuticals Ltd
ABN: 94 169 346 963
Level 15, 500 Collins St, Melbourne, VIC, 3000, AUSTRALIA
Email: investorrelations@paradigmbiopharma.com
Share your feedback
Discover